// App-Quantinova.ai

17016 : Trial Assessing Long-Term Use of PCSK9 Inhibition in Patients with Genetic LDL Disorders (TAUSSIG): Efficacy and Safety in Patients with Homozygous Familial Hypercholesterolemia Receiving Lipid Apheresis

Researchers

Presenter

  • Vladimir Blaha

Principal Investigators

  • Evan A. Stein

  • Frederick J. Raal

  • Christopher E. Kurtz

  • Narimon Honarpour

  • Feng Xu

  • John Gibbs

  • Scott M. Wasserman

  • Rob Scott

  • Patrick Couture

Medical Centers

  • Inst EM et IHU cardiometabolique, Paris, France

  • Metabolic and Atherosclerosis Res Ctr, Cincinnati, OH

  • University of Witwatersrand, Johannesburg, South Africa

  • Charles Univ, Hradec Kralove, Czech Republic

  • Ctr Hospier Univire de Quebec, Quebec, QC, Canada

Locations

  • Czech Republic

  • Canada

  • United States

  • France

  • South Africa

Companies

  • Amgen Inc.

Study Components

Therapeutic Area

  • Genetic Disorder

Disease

  • Hypercholesterolemia, Familial, 1

Biomarkers

  • Proprotein convertase subtilisin/kexin type 9

Drug/Treatment

  • Evolocumab

Outcome

  • N/A

Study Design

  • open label

  • single arm

  • double blind/blinded

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved